- Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial response
- Immunocore reports updated Phase 1 data of brenetafusp (IMC-F106C), an ImmTAC bispecific targeting PRAME, in immune checkpoint pre-treated cutaneous melanoma patients at ASCO 2024
- Immunocore to present at the Jefferies Global Healthcare Conference
- Immunocore converts Phase 2/3 TEBE-AM clinical trial into registrational Phase 3 trial evaluating KIMMTRAK for previously treated advanced cutaneous melanoma
- Immunocore reports first quarter financial results and provides a business update
- EQS-News: BB Biotech presents solid first-quarter results; biotech stock market impacted by shifting views on interest rates
- Immunocore announces upcoming presentation and posters at ASCO 2024
- Immunocore to present at upcoming investor conferences
- Immunocore presented two posters at CROI 2024
- Immunocore to present at upcoming investor conferences
More ▼
Key statistics
52-week range
Open | 36.80 |
---|---|
High | 36.80 |
Low | 36.80 |
Bid | 36.80 |
Offer | 38.20 |
Previous close | 38.00 |
Average volume | 40.22 |
---|---|
Shares outstanding | 50.01m |
Free float | 44.13m |
P/E (TTM) | -- |
Market cap | 2.08bn USD |
EPS (TTM) | -1.20 USD |
Data delayed at least 15 minutes, as of Jun 11 2024 07:00 BST.
More ▼